Calidi Biotherapeutics, Inc. (NYSEAM: CLDI)
Health Care · Biotechnology · US
$0.84
-18.74% today · -96.7% 1Y
Calidi Biotherapeutics, Inc. (NYSEAM: CLDI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.09M and employs 29 people.
Over the last twelve months the share price has lost 96.7%, trading between 0.79 and 27.04.
Tweenvest scores Calidi Biotherapeutics, Inc. across four factors: quality 36/100, value 27/100. Its strongest factor is quality.
CLDI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.09M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -33.30
- Dividend yield
- —
- Beta (5Y)
- 1.33
- 52-week high
- $27.04
- 52-week low
- $0.79
- Avg volume (3M)
- —
- Shares outstanding
- 3.70M
- Employees
- 29
- Next earnings
- —
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
- ISIN
- US3207035078
- Founded
- 2014
- Listed since
- Nov 1, 2021
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ernexa Therapeutics Inc.NasdaqCM: ERNA | $3.41M | $2.09 | -12.92% |
| National Graphite Corp.OTCPK: NGRC | $3.41M | $0.02 | +5.24% |
| Chosa Oncology ABNGM: CHOSA | $3.31M | Skr— | — |
| Affymax, Inc.OTCPK: AFFY | $3.10M | $0.04 | +2500.00% |
| Restart Life Sciences Corp.CNSX: HEAL | $3.06M | CA$0.07 | -6.67% |
| GRI Bio, Inc.NasdaqCM: GRI | $3.02M | $1.38 | -20.69% |
| Eocene Ltd.NasdaqCM: EOCN | $2.97M | $2.85 | -19.49% |
| Aptevo Therapeutics Inc.NasdaqCM: APVO | $2.92M | $1.62 | -9.50% |
Figures last refreshed Oct 18, 2026.